Journal of Clinical Oncology, Vol 12, 1607-1615, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Childrens Cancer Group

JR Geyer, PM Zeltzer, JM Boyett, LB Rorke, P Stanley, AL Albright, JH Wisoff, JM Milstein, JC Allen and JL Finlay
Children's Hospital and Medical Center, Seattle, WA.

PURPOSE: Very young children with CNS primitive neuroectodermal tumors (PNETs) and ependymomas have a poor prognosis and commonly have impairment of growth and cognitive abilities, in part resulting from radiotherapy. Thus, an intensive chemotherapeutic regimen was used to treat children less than 18 months of age at diagnosis. PATIENTS AND METHODS: Children were treated on a Childrens Cancer Group (CCG) protocol with an eight-drug chemotherapeutic regimen (vincristine, carmustine, procarbazine, hydroxyurea, cisplatin, cytarabine, prednisone, and cyclophosphamide) following surgery and postoperative staging. Delayed or reduced-volume radiotherapy was to be administered to all patients, but, in fact, was omitted in most cases. RESULTS: On central review of pathology, 82 children had diagnosis concordant with study entry criteria. Of these, 46 (56%) had posterior fossa (PF) PNET, eight (10%) had pineal PNET, 11 (12%) had nonpineal supratentorial PNET, 15 (18%) had ependymoma, and two had rhabdoid tumors. Fifty percent of tumor resections were complete, as verified by postoperative computed tomographic (CT) scan, and 23% of patients had metastatic disease at the time of diagnosis. Objective tumor response was documented following two cycles of chemotherapy in 28% of assessable patients. Toxicity of chemotherapy was primarily hematopoietic. Five children died of chemotherapy-related complications. Radiotherapy was administered to only nine patients before tumor progression. The 3-year progression-free survival (PFS) rates for PF PNET, pineal PNET, supratentorial nonpineal PNET, and ependymoma are 22% (SE = 6%), 0%, 55% (16%), and 26% (11%), respectively. The 3-year PFS rate for those children without metastatic disease was 29% (6%), as compared with 11% (6%) for those with metastatic disease. The only independent predictors of PFS were metastasis stage and location of the tumor within the pineal region. The median time to progression was 6 months. Twenty-four children completed the chemotherapeutic regimen without tumor progression; 19 are event-free survivors more than 2 years from diagnosis, only three of whom received radiation therapy. CONCLUSION: While overall survival in this group of very young patients is poor, a subset of children who have received only chemotherapy as adjuvant treatment remain free from tumor recurrence.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Dhall Medulloblastoma J Child Neurol, November 1, 2009; 24(11): 1418 - 1430. [Abstract] [PDF]

				S. Zacharoulis and L. Moreno Ependymoma: An Update J Child Neurol, November 1, 2009; 24(11): 1431 - 1438. [Abstract] [PDF]

				L. Lafay-Cousin and D. Strother Current Treatment Approaches for Infants with Malignant Central Nervous System Tumors Oncologist, April 1, 2009; 14(4): 433 - 444. [Abstract] [Full Text] [PDF]

				S. Rutkowski, N. U. Gerber, K. von Hoff, A. Gnekow, U. Bode, N. Graf, F. Berthold, G. Henze, J. E.A. Wolff, M. Warmuth-Metz, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy Neuro-oncol, January 1, 2009; 11(2): 201 - 210. [Abstract] [Full Text] [PDF]

				F. Nejat, M. El Khashab, and J. T. Rutka Initial Management of Childhood Brain Tumors: Neurosurgical Considerations J Child Neurol, October 1, 2008; 23(10): 1136 - 1148. [Abstract] [PDF]

				N. G. Gottardo and A. Gajjar Chemotherapy for Malignant Brain Tumors of Childhood J Child Neurol, October 1, 2008; 23(10): 1149 - 1159. [Abstract] [PDF]

				T. J. MacDonald Aggressive Infantile Embryonal Tumors J Child Neurol, October 1, 2008; 23(10): 1195 - 1204. [Abstract] [PDF]

				M. J. Binning, T. Niazi, C. A. Pedone, B. Lal, C. G. Eberhart, K. J. Kim, J. Laterra, and D. W. Fults Hepatocyte Growth Factor and Sonic Hedgehog Expression in Cerebellar Neural Progenitor Cells Costimulate Medulloblastoma Initiation and Growth Cancer Res., October 1, 2008; 68(19): 7838 - 7845. [Abstract] [Full Text] [PDF]

				L. Ridley, R. Rahman, M.-A. Brundler, D. Ellison, J. Lowe, K. Robson, E. Prebble, I. Luckett, R. J. Gilbertson, S. Parkes, et al. Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma Neuro-oncol, January 1, 2008; 10(5): 675 - 689. [Abstract] [Full Text] [PDF]

				B. Timmermann, R.-D. Kortmann, J. Kuhl, S. Rutkowski, C. Meisner, T. Pietsch, F. Deinlein, C. Urban, M. Warmuth-Metz, and M. Bamberg Role of Radiotherapy in Supratentorial Primitive Neuroectodermal Tumor in Young Children: Results of the German HIT-SKK87 and HIT-SKK92 Trials J. Clin. Oncol., April 1, 2006; 24(10): 1554 - 1560. [Abstract] [Full Text] [PDF]

				D. S. Ziegler, R. J. Cohn, G. McCowage, F. Alvaro, C. Oswald, R. Mrongovius, L. White, and for the Australian and New Zealand Children's Canc Efficacy of vincristine and etoposide with escalating cyclophosphamide in poor-prognosis pediatric brain tumors Neuro-oncol, January 1, 2006; 8(1): 53 - 59. [Abstract] [Full Text] [PDF]

				J. R. Geyer, R. Sposto, M. Jennings, J. M. Boyett, R. A. Axtell, D. Breiger, E. Broxson, B. Donahue, J. L. Finlay, J. W. Goldwein, et al. Multiagent Chemotherapy and Deferred Radiotherapy in Infants With Malignant Brain Tumors: A Report From the Children's Cancer Group J. Clin. Oncol., October 20, 2005; 23(30): 7621 - 7631. [Abstract] [Full Text] [PDF]

				E. Pan, M. Pellarin, E. Holmes, I. Smirnov, A. Misra, C. G. Eberhart, P. C. Burger, J. A. Biegel, and B. G. Feuerstein Isochromosome 17q Is a Negative Prognostic Factor in Poor-Risk Childhood Medulloblastoma Patients Clin. Cancer Res., July 1, 2005; 11(13): 4733 - 4740. [Abstract] [Full Text] [PDF]

				S. N. Chi, S. L. Gardner, A. S. Levy, E. A. Knopp, D. C. Miller, J. H. Wisoff, H. L. Weiner, and J. L. Finlay Feasibility and Response to Induction Chemotherapy Intensified With High-Dose Methotrexate for Young Children With Newly Diagnosed High-Risk Disseminated Medulloblastoma J. Clin. Oncol., December 15, 2004; 22(24): 4881 - 4887. [Abstract] [Full Text] [PDF]

				V. Kieffer-Renaux, C. Bulteau, J. Grill, C. Levy-Piebois, D. Couanet, A. Pierre-Kahn, O. Hartmann, and C. Kalifa Visual Agnosia After Treatment of a Posterior Fossa Ependymoma in a 16-Month-Old Girl J Child Neurol, September 1, 2001; 16(9): 698 - 704. [Abstract] [PDF]

				M. A. Grotzer, M. D. Hogarty, A. J. Janss, X. Liu, H. Zhao, A. Eggert, L. N. Sutton, L. B. Rorke, G. M. Brodeur, and P. C. Phillips MYC Messenger RNA Expression Predicts Survival Outcome in Childhood Primitive Neuroectodermal Tumor/Medulloblastoma Clin. Cancer Res., August 1, 2001; 7(8): 2425 - 2433. [Abstract] [Full Text] [PDF]

				J. Grill, M.-C. Le Deley, D. Gambarelli, M.-A. Raquin, D. Couanet, A. Pierre-Kahn, J.-L. Habrand, F. Doz, D. Frappaz, J.-C. Gentet, et al. Postoperative Chemotherapy Without Irradiation for Ependymoma in Children Under 5 Years of Age: A Multicenter Trial of the French Society of Pediatric Oncology J. Clin. Oncol., March 1, 2001; 19(5): 1288 - 1296. [Abstract] [Full Text] [PDF]

				A. W. Walter, R. K. Mulhern, A. Gajjar, R. L. Heideman, D. Reardon, R. A. Sanford, X. Xiong, and L. E. Kun Survival and Neurodevelopmental Outcome of Young Children With Medulloblastoma at St Jude Children's Research Hospital J. Clin. Oncol., December 1, 1999; 17(12): 3720 - 3728. [Abstract] [Full Text] [PDF]

				R. J. Packer, P. Cogen, G. Vezina, and L. B. Rorke Medulloblastoma: Clinical and biologic aspects Neuro-oncol, July 1, 1999; 1(3): 232 - 250. [Abstract] [PDF]

				P. K. Duffner, M. E. Horowitz, J. P. Krischer, P. C. Burger, M. E. Cohen, R. A. Sanford, H. S. Friedman, L. E. Kun, and the Pediatric Oncology Group (POG) The treatment of malignant brain tumors in infants and very young children: An update of the Pediatric Oncology Group experience Neuro-oncol, April 1, 1999; 1(2): 152 - 161. [PDF]

				P. M. Zeltzer, J. M. Boyett, J. L. Finlay, A. L. Albright, L. B. Rorke, J. M. Milstein, J. C. Allen, K. R. Stevens, P. Stanley, H. Li, et al. Metastasis Stage, Adjuvant Treatment, and Residual Tumor Are Prognostic Factors for Medulloblastoma in Children: Conclusions From the Children's Cancer Group 921 Randomized Phase III Study J. Clin. Oncol., March 1, 1999; 17(3): 832 - 832. [Abstract] [Full Text] [PDF]

				R. J. Packer and J. L. Finlay Chemotherapy for Childhood Medulloblastoma and Primitive Neuroectodermal Tumors Oncologist, December 1, 1996; 1(6): 381 - 393. [Abstract] [Full Text] [PDF]